Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Sept 14: After announcing Tuesday that its CRF1 antagonist, crinecerfont, met the primary efficacy endpoint in the Phase III CAHtalyst Adult Study for classic congenital adrenal hyperplasia, Neurocrine Biosciences reported good news on the neuro front
Seto H, Toba Y, Takada Y, et al
A Witschi , S Reddy, B Stofer, B H Lauterburg The systemic availability of oral glutathione
Zhao et al., 2023a)
Understanding the molecular determinants of resistance and using this to guide rational combination therapy approaches is fundamental to improve clinical outcomes for patients with cancer
First: Tolerance = Need for more to achieve original effect *
US$ 22.88
US$ 23.10
US$ 26.03
US$ 21.78
US$ 29.50
